SCIEX ZenoTOF 7600: Characterisation with the SCIEX ZenoTOF 7600

Advancing Biologics Characterisation with the SCIEX ZenoTOF 7600: Sensitivity, Resolution, and Speed

In today’s fast-evolving biopharmaceutical landscape, the need for robust analytical tools has never been greater. Biologics represent a broad and structurally diverse class of macromolecules, including proteins, peptides, nucleic acids, lipids, and glycans. Each of these biomolecules poses distinct analytical challenges due to their large size, inherent complexity, variability, and numerous different modifications. Their accurate characterization requires a mass spectrometry platform capable of delivering high sensitivity, exceptional resolution, and advanced fragmentation.

The SCIEX ZenoTOF 7600 system addresses these challenges by integrating cutting-edge QTOF technology with innovative hardware advancements that significantly enhance both qualitative and quantitative analytical capabilities. With its high-capacity ion trap (Zeno trap) for increased MS/MS sensitivity, electron-activated dissociation (EAD) for detailed structural elucidation, high-speed data acquisition, and a data independent acquisition strategy (SWATH, serial window acquisition of all theoretical mass spectra) the system sets a new benchmark in biotherapeutic analysis.

This blog explores the core technological innovations of the ZenoTOF 7600 and their direct impact on analytical workflows such as intact mass analysis, peptide mapping, PTMs (post-translational modifications). We will examine how its advanced fragmentation strategies, improved duty cycle efficiency, and high-resolution performance allow deeper insights into the structural integrity, modifications, and heterogeneity of therapeutic biomolecules and therefore translates into tangible advantages for biologics characterization and quality control.

Technological Innovations in ZenoTOF 7600

Zeno Trap Duty Cycle Enhancement
At the core of the ZenoTOF 7600 is an innovative Zeno trap — a high-capacity ion trap located immediately after the quadrupole collision cell. Conventional TOF instruments typically accelerate only about 5–25% of the available ions into the flight tube using pulsed ion injection. In contrast, the Zeno trap captures and stages these ions before sequentially releasing them in reverse mass order, thereby boosting the effective duty cycle to 90% or higher across the entire mass range. This clever strategy results in MS/MS sensitivity improvements ranging from 4- to 20-fold, ensuring that trace-level fragments can be reliably detected.

Electron Activated Dissociation (EAD)
Another key advancement is the integration of electron-activated dissociation (EAD). The EAD cell features tunable electron kinetic energies ranging from 0 to 25 eV. This function enables precise control over the fragmentation process, allowing for efficient yet gentle dissociation across a diverse range of analytes — from complex, multiply charged peptides to small molecules. In contrast to traditional CID (collision induced dissociation) spectra, the EAD approach produces fragmentation spectra that retain labile post-translational modifications, delivering the structural detail necessary for comprehensive molecular characterization. This fragmentation spectra often deliver a complementary information to the CID fragmentation.

Serial Window Acquisition of all Theoretical Mass Spectra (SWATH)
Building on the advanced EAD capabilities, the ZenoTOF 7600 takes its performance a step further by incorporating SWATH — a data-independent acquisition strategy that seamlessly integrates the high-duty cycle of the Zeno trap with the comprehensive power of Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH). Recent studies demonstrate that this combination can provide as an example a deeper proteomic coverage. By optimizing narrow isolation windows and increasing the number of acquired precursors, the ZenoTOF 7600 outperforms conventional SWATH-DIA methods, identifying up to 40% more protein groups in low-input samples (1).
Moreover, the improved duty cycle ensures the acquisition of reproducible MS/MS data across broad m/z ranges, enabling faster high-throughput analyses without compromising sensitivity and accuracy. This makes the system ideally suited for complex sample matrices analysis where both discovery-driven approaches and targeted quantification are essential.

High Speed Data Acquisition and Resolution
High-speed data acquisition is another hallmark of the system. Optimized ion optics combined with a pre-configured, high-speed LINAC collision cell and an advanced ion detector work together to achieve rapid acquisition rates. This configuration ensures the instrument maintains high mass accuracy and resolution, delivering data collection with accumulation times as brief as a few milliseconds — an essential feature for modern chromatographic separations. The system routinely achieves sub 2 ppm mass error and exceeds 40,000 resolution at m/z 1000, ensuring confident precursor mass assignments and separation.

The ZenoTOF Advantage: Enabling Biologics Workflows

Enhanced sensitivity on the ZenoTOF 7600 facilitates the detection and quantitation of trace level impurities, degradation products, and glycoforms that are pivotal for stability studies and biosimilarity assessments. By capturing up to 90% of MS/MS fragments, the platform achieves sensitivity gains of 4–20× over conventional TOF systems, ensuring that peptide fragments at the low picogram level can be consistently observed.

Preservation of labile PTMs through electron activated dissociation (EAD) enhances confidence in structural assignments by maintaining sensitive modifications—such as O linked glycans and phosphorylation—under gentle fragmentation conditions. This capability enables precise localization of critical PTMs, supporting functional analysis and detailed characterization of therapeutic proteins."

The platform's (UPLC-ZenoTOF 7600) quantitative robustness, high sensitivity, and rapid analysis capabilities, combined with its comprehensive suite of standard workflows for intact mass confirmation, peptide mapping, PTM profiling, and targeted MRM assays, make it ideally suited for QC release testing, method validation, and comparability studies as well as a wide range of other critical tests for biopharmaceuticals.

Biologics Classes for LC–ZenoTOF Applications

Monoclonal antibodies represent a cornerstone of therapeutic biologics, where LC–ZenoTOF workflows integrate intact mass analysis with high-resolution glycoform profiling to confirm accurate molecular weight distributions, assess batch-to-batch consistency, and localize critical post-translational modifications.

Therapeutic proteins (mAbs, enzymes) utilize peptide mapping and EAD-enabled fragmentation to verify primary sequences, identify degradation products, and monitor critical modifications, such as oxidations and deamidations, which provide insights into protein stability and suitability for long-term storage. Synthetic peptides are subjected to rigorous sequence confirmation to ensure accurate synthesis and purity. For proteins and peptides containing disulfide bonds, mapping may be performed to verify correct cysteine pairing, supporting structural integrity and functional activity. Meanwhile, peptide–drug conjugates undergo detailed analysis to confirm accurate payload-to-peptide ratios and assess linker stability under relevant storage and physiological conditions, ensuring consistent therapeutic performance.

Nucleic acid therapeutics—including mRNA, antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and aptamers—benefit from intact mass verification and impurity profiling to ensure sequence fidelity and chemical integrity. LC-MS analysis is critical for confirming nucleotide modifications, conjugate attachments, and quality attributes like capping efficiency and poly(A) tail integrity, supporting consistent therapeutic performance.

Glycans and glycoproteins benefit from the ZenoTOF’s gentle EAD fragmentation, which preserves fragile glycosidic bonds, enabling precise site-specific glycosylation mapping and comprehensive released glycan profiling—essential for biobetters and biosimilars to confirm structural consistency and functional similarity to reference products.
Finally, lipid- and protein–lipid conjugates in advanced delivery systems are characterized for lipid composition, conjugation sites, and low-level impurities within complex matrices.
In the upcoming posts, these biologics classes will be explored in depth, detailing LC–ZenoTOF strategies for QC release testing, purity and integrity assessment, identity confirmation, and advanced structural characterization.

Are you interested? Please do not hesitate to contact us. The experts from Laboratory Services will be happy to provide you with further information at any time. SCIEX ZenoTOF 7600 is one of many devices that are part of our technical equipment. Click here for the PDF Equipment Laboratory Services.

__________________________________________________________________________________

1. Gu Y. et al. Zeno SWATH for Enhanced Proteome Coverage in Low-Input Samples. Proteome Res. 23, 1120–1131 (2024). (sciex.com)
2. Smith J. A. et al. High-Duty Cycle Ion Trapping in QTOF Mass Spectrometry Using the Zeno Trap. Chem.96(5), 2345–2353 (2024). (sciex.com)
3. Lee T. H. & Brown D. F. Electron-Activated Dissociation for PTM-Preserving Fragmentation. Proteomics24, e2300412 (2024). (sciex.com)
4. Miller R. J. et al. Performance Characteristics of the SCIEX ZenoTOF 7600 Platform. Rapid Commun. Mass Spectrom.38, e9256 (2024). (sciex.com)
5. Wang P. & Zhao L. Quantitative Reproducibility in SWATH-DIA with Zeno Trap Integration. Cell. Proteomics23(8), 1500–1512 (2024). (sciex.com)
6. Jones H. A. et al. Applications of High-Speed LINAC Collision Cells in Modern QTOF Instruments. Am. Soc. Mass Spectrom.35(3), 456–467 (2025). (sciex.com)
7. Patel S. S. et al. Implementing Fast Acquisition Methods in CRO Workflows: A Case Study. Bioanalysis17(2), 89–101 (2025).
8. Li M. et al. Electron Activated Dissociation in Proteomic Analysis of Labile PTMs. Bioanal. Chem.417(12), 3456–3467 (2024). (pubmed.ncbi.nlm.nih.gov)